# JUN 2 2 2010

# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 Phone: (317) 521 - 3831 Fax: (317) 521 - 2324

Contact Person: Kathie Goodwin, Regulatory Principal Roche Diagnostics, Indianapolis Phone: 317-521-3831 Fax: 317-521-2324

Date Prepared: February $2 2 ^ { \mathfrak { n } ^ { \mathtt { d } } }$ , 2010

# Device Name

Proprietary names:Tina-Quant Ferritin Gen. 4 Assay

Common names: Ferritin Gen. 4 assay

Regulation: 21 CFR 866.5340

Classification names: Ferritin Immunological Test System

Product codes: DBF

# Device Description

The Tina-quant Ferritin Gen. 4 assay employs an immunoturbidimetric test in which human ferritin agglutinates with latex particles coated with anti-ferritin antibodies. The precipitate is determined turbidimetrically at $5 7 0 / 8 0 0 \ \mathrm { n m }$ .

# Intended use

In vitro test for the quantitative determination of ferritin in human serum and plasma on Roche automated clinical chemistry analyzers.

# 510(k) Summary, Continued

# Indications for Use

Immunological in vitro immunoturbidometric test for the quantitative determination of ferritin in human serum and plasma using Roche/Hitachi clinical chemistry analyzers. Measurements obtained by this device are used in the aid of diagnosis of diseases affecting iron metabolism in conjunction with other clinical and laboratory findings.

# Substantial equivalence

The Tina-quant Ferritin Gen. 4 assay is substantially equivalent to the TinaQuant Ferritin assay cleared in K964282.

Substantial equivalencecomparison

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Tina-quant Ferritin Gen. 4 Assay</td><td rowspan=1 colspan=1>Predicate Device: Tina-QuantFerritin (K964283)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In vitro test for the quantitativedetermination of ferritin in humanserum and plasma on Rocheautomated clinical chemistryanalyzers.</td><td rowspan=1 colspan=1>Immunoturbidimetric assay for the invitro quantitative determination offerritin in human serum and plasmausing automated clinical chemistryanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>ImmunoturbidimetricAnti-ferritin antibodies bound to latexreact with the antigen in the sample toform an antigen-antibody complex.Following agglutination, this ismeasured turbidimetrically.</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and Li-heparin, K2-EDTA orK3-EDTA plasma</td><td rowspan=1 colspan=1>Serum and heparinized, citrated or K2or K3-EDTA plasma</td></tr></table>

# 510(k) Summary, Continued

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Tina-quant Ferritin Gen. 4 Assay</td><td rowspan=1 colspan=1>Predicate Device: Tina-QuantFerritin (K964283)</td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=1>R1: TRIS Buffer, pH 7.5,stabilizing polyclonal antibodies,NaCl preservativeR3: Aqueous matrix containinglatex particles coated with anti-human ferritin antibodies (rabbit);preservative, stabilizers</td><td rowspan=1 colspan=1>R1: TRIS Buffer, pH 8.2, stabilizingpolyclonal antibodies, NaClPreservativeR2: Aqueous matrix containing latexparticles coated with anti-humanferritin antibodies (rabbit);preservative, stabilizers</td></tr><tr><td rowspan=1 colspan=1>LabeledInstrumentPlatform</td><td rowspan=1 colspan=1>Roche/Hitachi</td><td rowspan=1 colspan=1>Roche/Hitachi</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>C.f.a.s. Proteins</td></tr><tr><td rowspan=1 colspan=1>CalibrationFrequency</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>After lot change and as requiredfollowing quality control procedures</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Precinorm and Precipath Protein</td></tr><tr><td rowspan=1 colspan=1>ReagentStability</td><td rowspan=1 colspan=1>Unopened: Up to stated expirationdate of 24 monthsOpened:84 days, refrigerated on the analyzer</td><td rowspan=1 colspan=1>Unopened: Up to stated expirationdate of 15 monthsOpened:28 days, refrigerated on the analyzer</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>Roche/Hitachi 902:5 - 800 ng/mLRoche/Hitachi 912/917/Modular P:5 - 1000 ng/mL</td><td rowspan=1 colspan=1>Roche/Hitachi 902:5 - 400 ng/mLRoche/Hitachi 912/917/Modular P:15- 800 ng/mL</td></tr></table>

# 510(k) Summary, Continued

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=7>Tina-quant Ferritin Gen. 4 Assay</td><td rowspan=1 colspan=5>Predicate Device: Tina-QuantFerritin (K964283)</td></tr><tr><td rowspan=14 colspan=1>Precision</td><td rowspan=1 colspan=7>Precision was determined usinghuman samples and controls inaccordance with the CLSI EP5:requirements.I</td><td rowspan=14 colspan=5>Imprecision: Reproducibility wasdetermined using human samples andcontrols in an internal protocol: n=21.The following results were obtained.Within run  Between DaySample   Mean.          Mcao% CVng/ml   % CVng/ml.HS      32   6.0  32     5.6PNP     77   2.5  76     2.7PPP     333  1.2  329    1.3</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=2>RepeatabilityWithin run</td><td rowspan=2 colspan=2>IntermediatePrecision-Between Day</td><td rowspan=2 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Within run</td><td rowspan=1 colspan=2>Between Day</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean.ng/ml.</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>Mcaong/ml</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=2 colspan=1>HS</td><td rowspan=2 colspan=1>32</td><td rowspan=2 colspan=1>6.0</td><td rowspan=2 colspan=1>32</td><td rowspan=2 colspan=1>5.6</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Meanng/ml.</td><td rowspan=2 colspan=1>% CV</td><td rowspan=2 colspan=1>Meanng/mL</td><td rowspan=2 colspan=1>% CV</td><td rowspan=2 colspan=1></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>PNP</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>PNP</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>1.5</td><td></td><td></td><td rowspan=1 colspan=1>PPP</td><td rowspan=1 colspan=1>333</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>329</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>PPP</td><td rowspan=1 colspan=1>332</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>332</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>âˆ’</td><td></td></tr><tr><td rowspan=2 colspan=1>HS1</td><td rowspan=2 colspan=1>8.48</td><td rowspan=2 colspan=1>7.2</td><td rowspan=2 colspan=1>8.48</td><td rowspan=2 colspan=1>9.9</td><td></td><td></td></tr><tr><td rowspan=5 colspan=2></td></tr><tr><td rowspan=1 colspan=1>HS2</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>HS3</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>HS4</td><td rowspan=1 colspan=1>619</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>619</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>HS5</td><td rowspan=1 colspan=1>820</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>820</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=7>Limit of Blank = 3 ng/mLLimit of Detection = 5 ng/mL</td><td rowspan=1 colspan=5>Lower Detection Limit = 15 ng/mL</td></tr><tr><td rowspan=1 colspan=1>FunctionalSensitivity</td><td rowspan=1 colspan=7>Limit of Quantitation = 7 ng/mL</td><td rowspan=1 colspan=5>NA</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSpecificity</td><td rowspan=1 colspan=7>Same</td><td rowspan=1 colspan=5>The polyclonal antibodies used in theassay are specific for ferritin fromhuman liver and also recognize ferritinfrom human spleen. The antibodiesshow no cross reactivity to the humanferritin H subunit; which is the majorcomponent of human heart ferritin.</td></tr></table>

510(k) Summary, Continued   

<table><tr><td>Feature</td><td>Tina-quant Ferritin Gen. 4 Assay</td><td>Predicate Device: Tina-Quant Ferritin (K964283)</td></tr><tr><td>Interferences</td><td>Icterus: No Significant interference up to an I index of 60 (approximate conjugated and unconjugated bilirubin concentration: 60 mg/dL) Hemolysis: No significant interference up to an H index of 500 (approximate hemoglobin concentration: 500 mg/dL)</td><td>Icterus: No Significant interference up to an I index of 60 (approximate conjugated and unconjugated bilirubin concentration: 60 mg/dL) Hemolysis: No significant interference up to an H index of 500 (approximate hemoglobin concentration: 500 mg/dL)</td></tr><tr><td></td><td>Lipemia (Intralipid): No significant interference up to an Intralipid concentration of 1000 mg/dL on Roche/Hitachi 912, 917 and MODULAR P analyzers and up to an Intralipid concentration of 800 mg/dL on Roche/Hitachi 902 analyzers. There is poor correlation between the Intralipid concentration (corresponds to turbidity) and triglycerides concentration.</td><td>Lipemia (Intralipid): No significant interference up to an L index of 750 (approximate triglyceride concentration: 1500 mg/dL). There is poor correlation between turbidity and triglyceride concentration. Rheumatoid factors &lt;100 IU/ml do not</td></tr><tr><td></td><td>Rheumatoid factors &lt;1200 IU/ml do not interfere. No high-dose hook effect is seen up to a ferritin concentration of 80000 ng/mL on Roche/Hitachi 902/912/917/MODULAR P analyzers. Drugs: No interference was found at therapeutic concentrations using common drug panels.</td><td>interfere. A high-dose hook effect may occur at ferritin concentrations above 20,000 ng/mL (Roche/Hitachi 911/912/917/MODULAR P).</td></tr></table>

Tina-quant Ferritin Gen. 4 Assay

# 510(k) Summary, Continued

<table><tr><td rowspan=1 colspan=1>EY</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Tina-quant Ferritin Gen. 4 Assay</td><td rowspan=1 colspan=1>Predicate Device: Tina-QuantFerritin (K964283)</td></tr><tr><td rowspan=1 colspan=1>ExpectedValues</td><td rowspan=1 colspan=1>Men (20-60 yrs):30 - 400 ng/mLWomen (17  60 yrs):15- 150 ng/mL</td><td rowspan=1 colspan=1>Men:30 - 400 ng/mLWomen:15 -150 ng/mLChildren (3 months - 16 years):20- 200 ng/mL2nd _ 3rd month:80 - 500 ng/mL1t month:150 - 450 ng/mLUmbilical cord blood:50 - 250 ng/mL</td></tr><tr><td rowspan=1 colspan=1>MethodComparison</td><td rowspan=1 colspan=2>A comparison of the Roche Tina-quant Ferritin Gen. 4 assay on theRoche/Hitachi 917 analyzer (y) with the Roche Tina-quant Ferritin assay onthe same analyzer (x) using human serum and plasma samples gave thefollowing correlation (ng/mL):Passing Bablok:                                Linear regression:y = 0.987x + 0.040                            y = 0.987x + 0.591tau = 0.983                                      r = 0.999Number of samples measured: 94The sample concentrations were between 15.0 and 775 ng/mL (according themeasuring range of the predicate device).</td></tr></table>

Roche Diagnostics   
c/o Ms. Kathie Goodwin, MBA, MT (ASCP)BB, RAC   
Regulatory Affairs Principal   
9115 Hague Road, PO Box 50416   
Indianapolis, IN 46250-0416

Re: k100538 Trade/Device Name: Tina-Quant Ferritin Gen. 4 Regulation Number: 21 CFR $\$ 866.5340$ Regulation Name: Ferritin Immunological Test System Regulatory Class: Class II Product Code: DBF Dated: May 7, 2010 Received: May10, 2010

Dear Ms. Goodwin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such aditnalcontrols.Existng major egulatins affectig your device ca befund inTi, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathrm { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

![](images/1cab20c5ca4beab1832884ea93b06a9f9cb43dac4297f9fc47dee55b74d08c84.jpg)  
Page 2 - Ms. Kathie Goodwin

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): k100538

Device Name: Tina-Quant Ferritin Gen. 4

Indications for Use:

Immunological in vitro immunoturbidometric test for the quantitative determination of ferritin in human serum and plasma using Roche/Hitachi clinical chemistry analyzers. Measurements obtained by this device are used in the aid of diagnosis of diseases affecting iron metabolism in conjunction with other clinical and laboratory findings.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety